Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied?

Osteoporosis International

Volumn 24, Issue 4, 2013, Pages 1429-1436

  Van Der Goes, M C ^a   Jacobs, J W G ^a   Jurgens, M S ^a   Bakker, M F ^a   Van Der Veen, M J ^b   Van Der Werf, J H ^c   Welsing, P M J ^a   Bijlsma, J W J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ST JANSDAL HOSPITAL   (Netherlands)

^c DEPARTMENT OF SURGERY   (Netherlands)

Author keywords

Bone mineral density; Glucocorticoids; Osteoporosis; Rheumatoid arthritis

Indexed keywords

ALENDRONIC ACID; CALCIUM; GLUCOCORTICOID; METHOTREXATE; PREDNISONE; VITAMIN D;

ADULT; ADVERSE OUTCOME; AGE; AGED; ARTICLE; BODY WEIGHT; BONE DENSITY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; SPINE RADIOGRAPHY; TREATMENT OUTCOME;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HIP JOINT; HUMANS; LUMBAR VERTEBRAE; MALE; METHOTREXATE; MIDDLE AGED; OSTEOPOROSIS; PREDNISONE; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84876486677     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-012-2073-z     Document Type: Article

References (43)

1. Sokka T, Toloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F, Skakic V, Badsha H, Peets T, Baranauskaite A, Geher P, Ujfalussy I, Skopouli FN, Mavrommati M, Alten R, Pohl C, Sibilia J, Stancati A, Salaffi F, Romanowski W, Zarowny-Wierzbinska D, Henrohn D, Bresnihan B, Minnock P, Knudsen LS, Jacobs JW, Calvo-Alen J, Lazovskis J, Pinheiro Gda R, Karateev D, Andersone D, Rexhepi S, Yazici Y, Pincus T (2009) Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther 11(1):R7
2. Kirwan JR (1995) The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 333(3):142-146
3. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, van Zeben D, Dijkmans BA, Peeters AJ, Jacobs P, van den Brink HR, Schouten HJ, van der Heijde DM, Boonen A, van der Linden S (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350(9074):309-318
4. van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW (2002) Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 136(1):1-12
5. Wassenberg S, Rau R, Steinfeld P, Zeidler H (2005) Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 52(11):3371-3380
6. Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafstrom I (2005) Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 52(11):3360-3370
7. Kirwan JR, Bijlsma JW, Boers M, Shea BJ (2007) Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev (1):CD006356
8. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Zwinderman AH, Peeters AJ, de Jonge-Bok JM, Mallee C, de Beus WM, de Sonnaville PB, Ewals JA, Breedveld FC, Dijkmans BA (2007) Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 146(6):406-415
9. Choy EH, Smith CM, Farewell V, Walker D, Hassell A, Chau L, Scott DL (2008) Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis 67(5):656-663
10. van Tuyl LH, Plass AM, Lems WF, Voskuyl AE, Dijkmans BA, Boers M (2007) Why are Dutch rheumatologists reluctant to use the COBRA treatment strategy in early rheumatoid arthritis? Ann Rheum Dis 66(7):974-976
11. van der Goes MC, Jacobs JW, Boers M, Andrews T, Blom-Bakkers MA, Buttgereit F, Caeyers N, Choy EH, Cutolo M, Da Silva JA, Guillevin L, Holland M, Kirwan JR, Rovensky J, Saag KG, Severijns G, Webber S, Westhovens R, Bijlsma JW (2010) Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 69(6):1015-1021
12. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, Winthrop KL, Wong J, Zink A, van der Heijde D (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69(6):964-975
13. Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E, Geurts MA, van der Werf JH, van Albada-Kuipers GA, Jahangier-de Veen ZN, van der Veen MJ, Verhoef CM, Lafeber FP, Bijlsma JW (2012) Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 156(5):329-339
14. Laan RF, van Riel PL, van de Putte LB, van Erning LJ, van't Hof MA, Lemmens JA (1993) Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med 119(10):963-968
15. Hansen M, Podenphant J, Florescu A, Stoltenberg M, Borch A, Kluger E, Sorensen SF, Hansen TM (1999) A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects. Ann Rheum Dis 58(11):713-718
16. van Everdingen AA, Siewertsz van Reesema DR, Jacobs JW, Bijlsma JW (2003) Low-dose glucocorticoids in early rheumatoid arthritis: discordant effects on bone mineral density and fractures? Clin Exp Rheumatol 21(2):155-160
17. Capell HA, Madhok R, Hunter JA, Porter D, Morrison E, Larkin J, Thomson EA, Hampson R, Poon FW (2004) Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis 63(7):797-803
18. van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13(10):777-787
19. Shenstone BD, Mahmoud A, Woodward R, Elvins D, Palmer R, Ring EF, Bhalla AK (1994) Longitudinal bone mineral density changes in early rheumatoid arthritis. Br J Rheumatol 33(6):541-545
20. Keller C, Hafstrom I, Svensson B (2001) Bone mineral density in women and men with early rheumatoid arthritis. Scand J Rheumatol 30(4):213-220
21. Gough AK, Lilley J, Eyre S, Holder RL, Emery P (1994) Generalised bone loss in patients with early rheumatoid arthritis. Lancet 344(8914):23-27
22. Forslind K, Keller C, Svensson B, Hafstrom I (2003) Reduced bone mineral density in early rheumatoid arthritis is associated with radiological joint damage at baseline and after 2 years in women. J Rheumatol 30(12):2590-2596
23. Book C, Karlsson M, Akesson K, Jacobsson L (2008) Disease activity and disability but probably not glucocorticoid treatment predicts loss in bone mineral density in women with early rheumatoid arthritis. Scand J Rheumatol 37(4):248-254
24. Sokka T, Hakkinen A, Kautiainen H, Maillefert JF, Toloza S, Mork Hansen T, Calvo-Alen J, Oding R, Liveborn M, Huisman M, Alten R, Pohl C, Cutolo M, Immonen K, Woolf A, Murphy E, Sheehy C, Quirke E, Celik S, Yazici Y, Tlustochowicz W, Kapolka D, Skakic V, Rojkovich B, Muller R, Stropuviene S, Andersone D, Drosos AA, Lazovskis J, Pincus T (2008) Physical inactivity in patients with rheumatoid arthritis: data from twenty-one countries in a cross-sectional, international study. Arthritis Rheum 59(1):42-50
25. Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376(9746):1094-1108
26. Ernst E (1998) Exercise for female osteoporosis. A systematic review of randomised clinical trials. Sports Med 25(6):359-368
27. Karkkainen M, Rikkonen T, Kroger H, Sirola J, Tuppurainen M, Salovaara K, Arokoski J, Jurvelin J, Honkanen R, Alhava E (2009) Physical tests for patient selection for bone mineral density measurements in postmenopausal women. Bone 44(4):660-665
28. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, Curtis JR, Furst DE, McMahon M, Patkar NM, Volkmann E, Saag KG (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 62(11):1515-1526
29. Wade SW, Curtis JR, Yu J, White J, Stolshek BS, Merinar C, Balasubramanian A, Kallich JD, Adams JL, Viswanathan HN (2012) Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan. Bone 50:870-875
30. van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, vad de Putte LB (1989) Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1(8646):1036-1038
31. Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group Osteoporos Int 4(6):368-381
32. Hui SL, Gao S, Zhou XH, Johnston CC Jr, Lu Y, Gluer CC, Grampp S, Genant H (1997) Universal standardization of bone density measurements: a method with optimal properties for calibration among several instruments. J Bone Miner Res 12(9):1463-1470
33. Lu Y, Fuerst T, Hui S, Genant HK (2001) Standardization of bone mineral density at femoral neck, trochanter and Ward's triangle. Osteoporos Int 12(6):438-444
34. Ibanez M, Ortiz AM, Castrejon I, Garcia-Vadillo JA, Carvajal I, Castaneda S, Gonzalez-Alvaro I (2010) A rational use of glucocorticoids in patients with early arthritis has a minimal impact on bone mass. Arthritis Res Ther 12(2):R50
35. Bezerra MC, Carvalho JF, Prokopowitsch AS, Pereira RM (2005) RANK, RANKL and osteoprotegerin in arthritic bone loss. Braz J Med Biol Res 38(2):161-170
36. Mabilleau G, Pascaretti-Grizon F, Basle MF, Chappard D (2012) Depth and volume of resorption induced by osteoclasts generated in the presence of RANKL, TNF-alpha/IL-1 or LIGHT. Cytokine 57(2):294-299
37. The Joint Committee of the Medical Research Council and Nuffield Foundation on Clinical Trials of Cortisone, A.C.T.H., and Other Therapeutic Measures in Chronic Rheumatic Diseases (1954) A comparison of cortisone and aspirin in the treatment of early cases of rheumatoid arthritis. Br Med J 1(4873):1223-1227
38. de Nijs RN, Jacobs JW, Lems WF, Laan RF, Algra A, Huisman AM, Buskens E, de Laet CE, Oostveen AC, Geusens PP, Bruyn GA, Dijkmans BA, Bijlsma JW (2006) Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 355(7):675-684
39. Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, van de Ven CM, Dijkmans BA (2006) Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. Osteoporos Int 17(5):716-723
40. Hoes JN, Jacobs JW, Boers M, Boumpas D, Buttgereit F, Caeyers N, Choy EH, Cutolo M, Da Silva JA, Esselens G, Guillevin L, Hafstrom I, Kirwan JR, Rovensky J, Russell A, Saag KG, Svensson B, Westhovens R, Zeidler H, Bijlsma JW (2007) EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 66(12):1560-1567
41. CBO (2011) Guideline for osteoporosis and fracture prevention, third revision. [Richtlijn Osteoporose en fractuurpreventie, derde herziening]. http://www.cbo.nl/Downloads/1385/OsteoporoseRichtlijn%202011.pdf. Accessed 12 Jan 2012
42. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48(11):3224-3229
43. Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM (2010) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 21(11):1943-1951